Nextel Medical Corp. (MAJI)
| Market Cap | 424.93K -92.5% |
| Revenue (ttm) | -12.83K |
| Net Income | -661.35K |
| EPS | -0.02 |
| Shares Out | 84.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 262,500 |
| Open | 0.0053 |
| Previous Close | 0.0050 |
| Day's Range | 0.0050 - 0.0054 |
| 52-Week Range | 0.0017 - 0.2100 |
| Beta | -4.75 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 2, 2026 |
About Nextel Medical
Nextel Medical Corp., a clinical stage biotechnology company, develops ways to exploit the therapeutic potential of exosomes for the field of oncology in the United States. The company was formerly known as Exousia Pro, Inc. and changed its name to Nextel Medical Corp. in April 2026. Nextel Medical Corp. was incorporated in 2010 and is based in Saint Petersburg, Florida. [Read more]
Financial Performance
Financial StatementsNews
NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology
Capitalizing on a Global Hair Restoration Market Projected to Exceed $23 Billion, the Venture Integrates Advanced Exosome Delivery to Eliminate Microneedling and Reactivate Follicles ORLANDO, FL / ACC...
NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference
Company highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions. ORLANDO, FL / ACCESS New...
NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion
ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an ...
NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC
Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designat...
NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals
Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies. ORLANDO, FL / ACCESS Newswire / July 28, 2026 / NexTel Medical Corp. (...
NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform
Revised transaction expands NexTel's acquisition from JumpstartRx and NuevistraMed to Island 40 Group's broader growth platform, adding health services.
NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization
NexTel Medical, OTCPK: MAJI, announced the execution of Definitive Purchase Agreements to acquire two prominent telehealth and clinical solutions platforms
NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist
ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery sy...
Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the...
Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions
ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to annou...
Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to annou...
Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce...
Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement
ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced th...
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the e...
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it h...
Exousia Pro Announces Breakthrough In Exosome-Based Delivery
Successful loading of CBD material accelerates the path to revenue. ORLANDO, FL / ACCESS Newswire / November 4, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused ...
Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA
Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTC...
Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes
ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan...
Exousia Pro Reports Positive Outcome in Legal Proceeding
Focused on Protecting Shareholder Value and Advancing Core Business ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company f...
Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets
ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic ...
Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division
Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. ORLANDO, FL / ACCESS Newswire / September 8, 2025 / ...
Exousia Pro Creates New Subdivisions
Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter. The market for our new products is currently valued at $8.7 billion, projected to grow to $18.5 billi...
Exousia Pro Files Reg A.
ORLANDO, FLORIDA / ACCESS Newswire / June 25, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of c...
Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application
- Rigorous humanized mouse model enhances credibility and translatability of results - Key preclinical data to support FDA Orphan Drug Application - In vitro success signals potential for exosome-base...
Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview
A published paper shows NANOG Expression was almost 100% effective at eradicating tumor cells ORLANDO, FL / ACCESS Newswire / April 21, 2025 / MARIJUANA INC. (OTC PINK:MAJI), dba Exousia Pro, Inc., a ...